

RESEARCH ARTICLE

cPLA₂α^{-/-} sympathetic neurons exhibit increased membrane excitability and loss of N-Type Ca²⁺ current inhibition by M₁ muscarinic receptor signaling

Liwang Liu^{1,2#a}, Joseph V. Bonventre³, Ann R. Rittenhouse^{1,2#b*}

1 Program in Neuroscience, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, **2** Department of Physiology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, **3** Harvard Institute of Medicine, Harvard Medical School & Brigham and Women's Hospital, Boston, Massachusetts, United States of America

#a Current address: Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.

#b Current address: Department of Microbiology and Physiological Systems, Program in Neuroscience, University of Massachusetts Medical School, Worcester, United States of America.

* Ann.Rittenhouse@umassmed.edu



OPEN ACCESS

Citation: Liu L, Bonventre JV, Rittenhouse AR (2018) cPLA₂α^{-/-} sympathetic neurons exhibit increased membrane excitability and loss of N-Type Ca²⁺ current inhibition by M₁ muscarinic receptor signaling. PLoS ONE 13(12): e0201322. <https://doi.org/10.1371/journal.pone.0201322>

Editor: Alexander G. Obukhov, Indiana University School of Medicine, UNITED STATES

Received: May 24, 2018

Accepted: July 11, 2018

Published: December 17, 2018

Copyright: © 2018 Liu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The work was funded by grants from the National Institutes of Health (NIH): National Institute of Neurological Disorders and Stroke. URL = <https://www.ninds.nih.gov/>. #NS34195 (ARR); NIH: National Institute of Digestive Disorders and Kidney. URL = <https://www.niddk.nih.gov/>. #DK39773 and #DK72381 (JVB).

Abstract

Group IVa cytosolic phospholipase A₂ (cPLA₂α) mediates GPCR-stimulated arachidonic acid (AA) release from phosphatidylinositol 4,5-bisphosphate (PIP₂) located in plasma membranes. We previously found in superior cervical ganglion (SCG) neurons that PLA₂ activity is required for voltage-independent N-type Ca²⁺ (N-) current inhibition by M₁ muscarinic receptors (M₁Rs). These findings are at odds with an alternative model, previously observed for M-current inhibition, where PIP₂ dissociation from channels and subsequent metabolism by phospholipase C suffices for current inhibition. To resolve cPLA₂α's importance, we have investigated its role in mediating voltage-independent N-current inhibition (~40%) that follows application of the muscarinic agonist oxotremorine-M (Oxo-M). Preincubation with different cPLA₂α antagonists or dialyzing cPLA₂α antibodies into cells minimized N-current inhibition by Oxo-M, whereas antibodies to Ca²⁺-independent PLA₂ had no effect. Taking a genetic approach, we found that SCG neurons from cPLA₂α^{-/-} mice exhibited little N-current inhibition by Oxo-M, confirming a role for cPLA₂α. In contrast, cPLA₂α antibodies or the absence of cPLA₂α had no effect on voltage-dependent N-current inhibition by M₂/M₄Rs or on M-current inhibition by M₁Rs. These findings document divergent M₁R signaling mediating M-current and voltage-independent N-current inhibition. Moreover, these differences suggest that cPLA₂α acts locally to metabolize PIP₂ intimately associated with N- but not M-channels. To determine cPLA₂α's functional importance more globally, we examined action potential firing of cPLA₂α^{+/+} and cPLA₂α^{-/-} SCG neurons, and found decreased latency to first firing and interspike interval resulting in a doubling of firing frequency in cPLA₂α^{-/-} neurons. These unanticipated findings identify cPLA₂α as a tonic regulator of neuronal membrane excitability.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Following stimulation of a subset of G-protein coupled receptors (GPCRs), acutely activated group IVa cytosolic phospholipase A₂ (cPLA₂α) exhibits high specificity for liberating AA from the sn-2 position of PIP₂ [1–3]. cPLA₂α activity promotes acute inflammatory responses and oxidative stress associated with neurological disorders, spinal cord injuries, and stroke [4–9]. Additionally, there is growing interest in understanding links between cPLA₂α and psychiatric disorders (see Rapoport, 2014[10] for review). cPLA₂α also participates in cellular processes of neurons critical for normal functioning, such as synaptic plasticity [11–15] and ion channel modulation [16–18].

Previously, we found that bath application of AA mimics the voltage-independent inhibition of whole-cell L- and N-type Ca²⁺ current in superior cervical ganglion (SCG) neurons following stimulation of a M₁R signaling cascade [19–21], referred to as the slow pathway [22]. Similar results were found for L- and N-current from recombinant Ca_v1.3 and Ca_v2.2 channels, respectively [16, 23]. M₁R signaling stimulates increased release of free AA from SCG neurons implicating the acute activation of a PLA₂ in the slow pathway following muscarinic stimulation [19]. We tested for this possibility and found that pharmacologically antagonizing PLA₂ activity during M₁R stimulation minimized inhibition of both whole-cell L- and N-current in SCG neurons [19–21] and recombinant N-current [23]. These findings support the notion that a particular PLA₂ may participate in M₁R-mediated modulation of Ca²⁺ channel activity.

cPLA₂α may be the PLA₂ involved in slow pathway modulation of N-type Ca²⁺ (N-) channels. Binding of PIP₂ to L- and N-channels is necessary for normal channel opening [24, 25]. Rapid decreases in plasma membrane levels of PIP₂ following activation of a voltage-stimulated phosphatase (VSP), which converts PIP₂ to PIP, rapamycin-induced translocation of inositol-lipid phosphatases, or M₁R stimulation [24, 25], decreases channel open probability. cPLA₂α participation in PIP₂ metabolism follows an initial series of steps previously described for the slow pathway where M₁Rs via G_q stimulate phospholipase C (PLC) to initiate PIP₂ metabolism (see [26]). We identified cPLA₂α as the particular PLA₂ mediating L-current inhibition using cPLA₂α antibodies as functional antagonists [19]. Moreover, fatty acid release and L-current inhibition were both lost in SCG neurons lacking cPLA₂α. These findings suggest that cPLA₂α may be the PLA₂ mediating N-current inhibition during M₁R stimulation by metabolizing PIP₂ molecules associated with N-channels.

Our hypothesis that cPLA₂α activity may be required for N-current inhibition by M₁R signaling is at odds with an alternative model where M₁R signaling stimulates PLC, which metabolizes PIP₂ once it dissociates from an N-channel. In this latter model, there is no requirement for cPLA₂α activity [27, 28]. Consistent with a signaling pathway independent of PLA₂, normal M₁R mediated N-current inhibition was observed in the perforated-patch configuration in SCG neurons in the presence of pharmacological antagonism of PLA₂ activity [24]. These results raise questions concerning a role for PLA₂ in mediating N-channel modulation. We applied additional pharmacological, biochemical and genetic approaches to determine whether cPLA₂α mediates N-current as well as L-current inhibition by M₁R signaling in SCG neurons. We present results which show that cPLA₂α does serve critical roles in normal neuronal functioning: mediating N-current modulation by M₁R signaling and more broadly by regulating membrane excitability.

Materials and methods

Ethical approval

All protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Massachusetts Medical School. The IACUC specifically approved animal use

for this study, which was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All efforts were made to minimize animal suffering.

Acutely dissociated SCG neurons

Acutely dissociated SCG neurons were isolated following CO₂ exposure and/or decapitation from neonatal 1–3 day-old Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) following the methods of Liu et al. (2001) and from C57BL/6J X 129/Sv mice lacking cPLA₂α (10–16 weeks old) created in the Bonventre laboratory [29] were obtained following decapitation using the method of Liu et al. (2006). Briefly, each ganglion was removed from the neck region, cut into several pieces, and then transferred into a 25 cm² culture flask containing 5 ml EBSS, 0.5 mg/ml trypsin (Worthington Biochemicals, Freehold, NJ), 1 mg/ml collagenase D (Roche Applied Science, Indianapolis, IN), 0.1 mg/ml DNaseI (Roche Applied Science), 3.6 g/l glucose and 10 mM HEPES. The SCG pieces were incubated at 34°C in a 5% CO₂/95% O₂ gassed, shaking water bath. After 1 hour, cell somata were dissociated from ganglion fragments by trituration. The dissociation was stopped by adding 5 ml of Modified Eagle's Medium (Gibco, Carlsbad, CA) supplemented with 10% FBS, 4 mM glutamine and 100 IU/ml pen-100 µg/ml streptomycin. Cells were pelleted by centrifuging at 500 × g for 5 minutes. The resulting pellet was resuspended in the supplemented DMEM. Dissociated cells from the equivalent of 1 SCG were plated on poly-L-lysine (Sigma) coated glass coverslips and incubated in Falcon 35 mm² dishes at 37°C in a 5% CO₂ environment. Cells were used within 48 hrs of plating. To study the effects of activation of M₁Rs on N-channel activity, SCG neurons were preincubated with 500 ng/ml PTX for at least 5 hours, to remove inhibition of N-current by activated M₂/M₄ muscarinic receptors coupling to the PTX-sensitive, membrane-delimited pathway [26]. Disabling the membrane-delimited pathway isolates N-current modulation by the M₁R, PTX-insensitive, slow pathway.

Electrophysiological methods

Standard whole-cell recording methods were used following the methods of Liu et al [23, 30]. Currents and action potentials (APs) were obtained from SCG neurons, plated on poly-L-lysine coverslips and placed in a glass-bottomed recording chamber holding approximately 25 µl of bath solution. Electrodes were pulled from borosilicate glass capillaries (Drummond Scientific Company, Broomall, PA) and fire-polished to a tip diameter of ~1 µm. The total pipette access resistance ranged from 2.0–2.5 MΩ.

For whole-cell or perforated-patch N-current recordings, cells were clamped to -90 mV and 20 ms test pulses were delivered every 4 sec. N-current amplitude was measured 15 ms after the start of the test pulse. To test for voltage-dependent inhibition, a prepulse protocol was used that alternated every 4 secs between a 200-ms prepulse to +80 mV (+PP) or no prepulse (-PP). After a brief (5-msec) return to -90 mV, the membrane voltage was stepped to +10 mV for 100 msec. M-current was elicited by holding the membrane potential at -20 mV and applying a 500-ms hyperpolarizing pulse to -60 mV every 4 sec. M-current amplitude was measured at -60 mV from the decaying time course of deactivating current as the difference between the average of a 10-ms segment, taken 20–30 ms into the hyperpolarizing step and the average during the the last 50 ms of that step. For current-clamp recordings, APs were generated by injecting 40–200 pA of current for either 400 or 1,000 ms. Both voltage-clamp and current-clamp traces were recorded using an Axopatch 200A amplifier (Molecular Devices), a 1401 *plus* interface and Signal 2.16 software (Cambridge Electronic Design (CED), England). Traces were

low-pass filtered at 5 kHz using the amplifier's Bessel filter, digitized at 20–40 kHz and saved on a personal computer. All recordings were made at room temperature (20–24°C).

Recording solutions

For perforated-patch and whole-cell recordings, the same bath and internal solutions were used. The bath solution contained (in mM): 135 N-methyl-D-glucamine (NMG)-Asp, 10 4-(2-hydroxyethyl)-1-piperazineethane-sulfonic acid (HEPES), 20 barium acetate and 0.0005 tetrodotoxin (TTX; Sigma) (293 mOsM). The L-channel antagonist nimodipine (NMN, 1 μM) was included in the bath to minimize the small amount of L-current present in SCG neurons unless otherwise stated. The pipette solution contained (in mM): 123 Cs-Asp, 10 HEPES, 0.1 1,2-bis(o-Aminophenoxy) ethane-N,N,N',N'-tetraacetic acid (BAPTA; Sigma), 5 MgCl₂, 4 ATP (Sigma) and 0.4 GTP (Sigma) (264 mOsM). pH for all solutions was adjusted to 7.5. For perforated patch recordings, a 60 mg/ml stock solution of amphotericin B (Sigma) was made up in dimethyl sulphoxide fresh each day. Amphotericin B was added to an aliquot of pipette solution every 2 hours for a final concentration of 0.1 mg/ml.

For measuring whole-cell M-current, the external solution contained in mM: 160 NaCl, 2.5 KCl, 2 CaCl₂, 1 MgCl₂, 10 HEPES, 8 glucose, 0.0005 TTX. The pH was adjusted to 7.5 with NaOH. The internal solution contained in mM: 175 KCl, 5 HEPES, 5 MgCl₂, 0.1 BAPTA, 4 ATP, 0.4 GTP. The pH was adjusted to 7.5 with KOH.

The external solution for recording APs in the current-clamp mode contained (in mM): 120 NaCl, 3 KCl, 4 MgSO₄, 1 NaH₂PO₄, 25 NaHCO₃, 2 CaCl₂ (321 mOsM); the pH was adjusted to 7.5 with NaOH. The pipette solution contained (in mM): 110 K gluconate, 30 KCl, 1 MgSO₄, 1 CaCl₂, 0.1 BAPTA, 10 HEPES, 4 ATP and 0.4 GTP (297 mOsM); and the pH adjusted to 7.5 with KOH.

NMN (Sigma), oleyloxyethyl phosphorylcholine (OPC; Calbiochem, La Jolla, CA, or Biomol, Plymouth Meeting, PA) and methyl arachidonoyl fluorophosphonate (MAFP; Biomol) were prepared as stock solutions in 100% ethanol and diluted with bath solution to a final ethanol concentration less than 0.11%. The maximal final concentration of ethanol had no significant effect on whole-cell currents. Stock solutions of Oxo-M (Tocris, Ellisville, MO), ω-agatoxin IVA (ω-Aga IV; Sigma), SNX-482 (Sigma), PTX (List Biological Laboratories, Inc., Campbell, CA) and TTX (Sigma) were made up in double distilled water. cPLA₂ (Cell Signaling, Beverly, MA) and iPLA₂ (Upstate, Charlottesville, VA) antibodies were diluted directly into the pipette solution.

Statistical analysis

Data were analyzed using Patch and Signal (CED), Excel (Microsoft, Seattle, WA) and Origin (MicroCal, Northampton, MA) programs. Data were expressed as means ± SEM. Statistical significance was determined by either a two-way Student's *t*-test for two means or a two-tailed paired *t*-test. Data were designated as significant if $p < 0.05$.

Results

Antagonizing PLA₂ activity minimizes N-current inhibition by Oxo-M in perforated-patch recordings

We found previously that treating SCG neurons for two minutes with the PLA₂ antagonist OPC (10 μM) minimized whole-cell N-current inhibition by Oxo-M [21]. However, Gamper et al. [24] found that, when using the perforated-patch recording configuration, bath application of OPC (10 μM) for two minutes prior to Oxo-M had no effect on N-current inhibition.

To determine whether technical differences between the two recording configurations could explain the disparity in results, we tested OPC's ability to block N-current inhibition in SCG neurons by the slow pathway (Fig 1A) using the perforated-patch configuration. Cells were




Fig 1. PLA₂ antagonists reduce N-current inhibition by Oxo-M in neonatal rat SCG neurons. (A and B) Schematics showing the two muscarinic signaling pathways in SCG neurons along with the antagonists used that resulted in isolation of N-current by the slow pathway. Control inhibition by 10 μM Oxo-M is illustrated in the plot of current amplitudes vs time (C) and in the individual sweeps (D) taken from the time course of a perforated-patch recording. NMN (1 μM) was included in the bath to block L-current. (E) Summary of effects of PLA₂ antagonists on N-current inhibition. OPC significantly reduces inhibition of perforated-patch N-current ($***p \leq 0.0015$, $n = 5$) and MAFP (10 μM) significantly reduces inhibition of whole-cell N-current. $**p \leq 0.015$, compared to inhibition by Oxo-M alone (open bars) using a two-tailed *t*-test for two means ($n = 6-9$). The presence of OPC (10 μM) in the bath for 3 min prior to challenging cells with Oxo-M blocks N-current inhibition, illustrated in a sample time course (F) and in individual traces (G) taken from the time course. (H) Summary of the effects of wortmannin on current inhibition by Oxo-M (open bar) and on current recovery following washout (black bars). M-current amplitude following Oxo-M washout does not recover. N-current inhibition is significantly different than in the absence of wortmannin ($*p \leq 0.05$, using a two-tailed *t*-test for two means when comparing to data in Fig 1E). Significant N-current recovery occurs following washout ($*p \leq 0.03$, two-way *t*-test for two means) ($n = 3-9$). Example time course (I) and individual traces (J) of the reversible N-current inhibition by Oxo-M in the presence of wortmannin.

<https://doi.org/10.1371/journal.pone.0201322.g001>

pretreated with PTX to block the membrane-delimited pathway (Fig 1B). Under control conditions, Oxo-M (10 μM) reversibly inhibited N-current 30 ± 4.3% [CON = 416 ± 33 pA; Oxo-M = 288 ± 27 pA] (n = 10, *p* < 0.0003) when comparing inhibited to control current amplitudes (Fig 1C–1E). When cells were exposed to OPC for 2 minutes, Oxo-M inhibited N-current by 19% (n = 2), suggesting incomplete antagonism of PLA₂. Therefore we increased the pre-incubation time to 3 minutes and now found minimal (4.3 ± 1.1%, n = 5) N-current inhibition by Oxo-M (Fig 1E–1G), similar to OPC's actions observed previously in the whole-cell configuration [21]. These results reproduce the findings of Gamper et al [24] and demonstrate that a longer preincubation time with OPC is necessary, when recording in the perforated-patch configuration, in order to observe antagonism of slow pathway modulation of N-current.

PLA₂ participates in muscarinic inhibition of whole-cell Ca²⁺ current in cortical neurons

To investigate how widespread is PLA₂'s involvement in muscarinic modulation of voltage-gated Ca²⁺ channel activity, we tested whether Oxo-M inhibits whole-cell Ca²⁺ currents of prefrontal cortex (PFC) pyramidal neurons (S1 Methods and S1 Fig). These neurons receive muscarinic input from the nucleus basalis and express M₁Rs [31]. Oxo-M inhibited whole-cell currents by 35 ± 11% (n = 2). We then investigated whether antagonizing PLA₂ minimizes current inhibition and found that in the presence of OPC, Oxo-M no longer inhibited the whole-cell current (-0.3 ± 7.2%; n = 3). These results suggest that PLA₂ participates in M₁R-induced Ca²⁺ current inhibition in central neurons as well as peripheral sympathetic neurons. Thus, these OPC experiments are consistent with a role for PLA₂ in N-current inhibition and that its participation in Ca²⁺ current modulation may be widespread.

M- and N-current modulation by M₁Rs exhibit different pharmacological sensitivities

In addition to L- and N-current inhibition by M₁R signaling, the KCNQ2/3 channel current, M-current, is inhibited by M₁R signaling via decreased PIP₂ levels in the membrane by a pathway that appears independent of PLA₂ [19, 32–34]. Consistent with these findings, we previously found that OPC had no effect on whole-cell native M-current inhibition [19]. Thus, we have used M-current modulation by M₁R signaling as a negative control for selective N-channel modulation by PLA₂. In so doing we have identified pharmacological differences in inhibition of these two channels. In addition to a different sensitivity to OPC, a salient feature of M-current is its irreversibility when PIP₂ resynthesis is blocked by wortmannin in whole-cell and perforated-patch configurations [24, 32]. Wortmannin is a mixed action antagonist that when used at high concentrations (50 μM) inhibits PI4K activity thus limiting synthesis of PIP₂ [35], but has no effect on basal M-current amplitude or the magnitude of M-current inhibition by Oxo-M.

We compared the effects of wortmannin, on whole-cell M- versus N-current inhibition by Oxo-M to test for further differences in the properties of their respective signaling cascades. When present in the bath solution, 50 μM wortmannin resulted in rapid run down of N-current. However, a lower concentration of wortmannin (10 μM) blocked washout of the muscarinic effect for M-current (Fig 1H), similar to what had been observed previously at higher concentrations [32]. Therefore, we tested the effects of this lower concentration of wortmannin on N-current inhibition. We found that the magnitude of N-current inhibition by Oxo-M was significantly less when 10 μM wortmannin was introduced into the bath solution at least 2 min before exposing SCG neurons to Oxo-M (*p* ≤ 0.01; n = 3–7/group). Under these

conditions, inhibition reversed upon washout of Oxo-M (Fig 1H–I), similar to wortmannin's actions on L-current inhibition by Oxo-M [19]. Our findings with a lower wortmannin concentration differ from previous studies of older SCG neurons treated with higher concentrations [24, 36]. Nevertheless, these results are consistent with the possibility that M- and N-current inhibition by M₁R signaling is mediated by diverging signal transduction cascades.

In addition to differences in the effects of OPC and wortmannin, we found that including BSA in the bath solution blocks N-current inhibition by M₁R signaling [37], whereas M-current inhibition by Oxo-M remained robust ($p \leq 0.00015$) in the presence of BSA (445 ± 110 pA in the presence of BSA, 160.9 ± 47.8 pA in the presence of BSA+Oxo-M; $n = 7$). However, while these experiments suggest differences in signaling, they do not identify whether one key difference is the participation of cPLA₂α in N-current but not M-current inhibition.

Identification of cPLA₂α as the specific PLA₂ participating in N-current inhibition

Our previous studies demonstrated that L-current inhibition by M₁Rs specifically required cPLA₂α, suggesting that it may also mediate N-current modulation [19]. To test this possibility, we examined whether MAFP, an irreversible antagonist that exhibits selectivity for cPLA₂α [38], blocks N-current inhibition. Preincubation with MAFP (10 μM) for 4 minutes resulted in less N-current inhibition by Oxo-M ($22.3 \pm 7.5\%$; $n = 9$) compared to the control group ($29 \pm 5.8\%$, $n = 6$), consistent with a role for cPLA₂ in the pathway (Fig 1E). However, MAFP alone significantly inhibited N-current by $29 \pm 18\%$ ($p \leq 0.001$; $n = 9$), raising concern about nonspecific effects on N-channels.

Therefore, we took a more specific biochemical approach to identify the PLA₂ participating in the slow pathway by using selective antibodies as functional antagonists (Fig 2A). When an Ab to cPLA₂α (1:500) was dialyzed into SCG neurons for at least 5 minutes, Oxo-M inhibited N-current $11 \pm 2.7\%$ ($n = 8$; Fig 2B and 2C). In contrast, Oxo-M elicited normal N-current inhibition of $41 \pm 7.0\%$ ($n = 4$), when Abs to iPLA₂ (1:200) were dialyzed into cells (Fig 2B and 2C). Basal current levels in cells dialyzed with cPLA₂α Ab (371 ± 62 pA) compared to those dialyzed with iPLA₂ Ab (536 ± 156 pA) did not differ significantly ($p \leq 0.3$), indicating that the antibodies had no effect of their own on N-current amplitude. Moreover, we previously found that dialyzing SCG neurons with IgG also had no effect on N-current inhibition by Oxo-M [20] reporting an average inhibition of $35.4 \pm 3.4\%$.

To examine selectivity for M₁R-mediated N-current inhibition, we tested whether the cPLA₂α Ab had any effect on N-current inhibition by M₂/M₄Rs. As with the OPC experiments, the Ab experiments were performed with PTX-treated cells. In order to invoke simultaneously both M₂/M₄R voltage-dependent and M₁R voltage-independent N-current inhibition (Fig 2B), we continued to use a pipette solution containing a low BAPTA (0.1 mM) concentration, but eliminated neuron preincubation with PTX (Fig 2D). The two forms of inhibition can be distinguished using a prepulse voltage protocol [39] that was initiated immediately following breakthrough (see methods for further details). Under these conditions, a small facilitation of the whole-cell N-current was observed following a prepulse (Fig 2E and 2F) most likely due to tonic N-current inhibition by Gβγ [20]. Upon exposure to Oxo-M, N-current was robustly inhibited. Inhibition was partially reversed with a prepulse, revealing the amount of M₂/M₄R mediated voltage-dependent inhibition. The remaining voltage-independent N-current inhibition in SCG neurons is known to be mediated by M₁R signaling [40, 41]. However, when neurons were dialyzed with the cPLA₂α Ab, prepulses now relieved all of the inhibition by Oxo-M, consistent with inhibition occurring solely via the M₂/M₄R mediated voltage-dependent pathway and little to none by the M₁R voltage-independent pathway (Fig 2F).




Fig 2. cPLA₂α is required for inhibition of whole-cell N-current by Oxo-M in SCG neurons. (A) Schematic of experimental conditions. (B) Individual traces illustrating that dialyzing SCG neurons with cPLA₂ Abs (Abs, 1:500) minimizes N-current inhibition (n = 8) compared to robust current inhibition (41.2 ± 7.02%) of neurons dialyzed with iPLA₂ Abs (1:200; n = 4). (C) Summary bar graph illustrating the significant difference ($***p \leq 0.001$) between the average current inhibition with cPLA₂ versus iPLA₂ Abs (n = 4–8/group). (D) Schematic of membrane-delimited pathway. (E) Individual traces showing N-current inhibition by Oxo-M (red traces) in cells dialyzed with Ab in the absence (-PP) or following (+PP) a prepulse. (F) Summary bar graph of control (open bars) and Ox-M inhibited (red bars) N-current amplitude with -PP or +PP protocols. Following Oxo-M, significant inhibition ($*p \leq 0.05$; n = 5) occurred in the absence of a prepulse (-PP), which was completely relieved ($**p \leq 0.005$; n = 5/group) with a prepulse (+PP). (G) Schematic showing the cPLA₂ Ab should not affect M-current inhibition by Oxo-M. (H) Example time course showing rapid, reversible M-current inhibition in SCG neurons dialyzed with Ab. (I) Summary bar graph showing significant ($***p \leq 0.0005$; n = 8) M-current inhibition by Oxo-M.

<https://doi.org/10.1371/journal.pone.0201322.g002>

These findings complement the OPC results and are consistent with the cPLA₂ α Ab selectively preventing M₁R signaling.

Previous OPC experiments suggested that M-current inhibition by M₁R signaling occurs independently of cPLA₂ α activity [19]. Therefore, we hypothesized that while the cPLA₂ α Ab selectively prevented N-current inhibition by M₁R signaling, it would have no effect on M-

current modulation. We tested this prediction by using the same dialysis protocol as used with N-current modulation (Fig 2G). As predicted, robust M-current inhibition by Oxo-M was observed in SCG neurons dialyzed with the cPLA₂α Ab (Fig 2H and 2I). Taken together these studies suggest that M- and N-current are modulated by diverging signal transduction pathways where N-current but not M-current inhibition requires active cPLA₂α.

N-channels in cPLA₂α^{-/-} SCG neurons are resistant to modulation by the slow pathway

Lastly, we took a genetic approach to verify a requirement for cPLA₂α by testing the effect of Oxo-M on whole-cell N-current in SCG neurons isolated from C57BL/6J x SV-129 mice lacking cPLA₂α [29]. The cPLA₂α^{+/+} C57BL/6J and SV129 mouse strains have a naturally occurring background mutation in Group IIa PLA₂ (sPLA₂) resulting in a loss of sPLA₂ activity [42, 43]. Consequently, mice lacking cPLA₂α are double mutant, but for simplicity are referred to as cPLA₂α^{-/-} mice. Whole-cell N-currents were recorded from SCG neurons isolated from cPLA₂α^{-/-} mice (10–16 weeks) and compared to currents from conspecific cPLA₂α^{+/+} littermates. Mouse SCG neurons express multiple voltage-gated Ca²⁺ channels [19, 44]. Therefore to isolate N-current, a pharmacological strategy previously developed to isolate specific Ca²⁺ currents from mouse SCG neurons was employed [19]. Neurons were pre-incubated with ω-Aga IVa (200 nM) for at least 30 min to irreversibly block any P/Q-type Ca²⁺ current. Recordings were completed within 20 min of the preincubation period. NMN (1 μM) and SNX-482 (20 nM) were added to the bath solution to block L- and R-type Ca²⁺ channels, respectively (Fig 3A). Under these conditions, Oxo-M inhibited N-current by 42 ± 4.7% (n = 5) in cPLA₂α^{+/+} SCG neurons, but only 9.5 ± 4.7% (n = 5) in cPLA₂α^{-/-} neurons (Fig 3B–3D). The magnitude of N-current inhibition by Oxo-M differed significantly between cPLA₂α^{+/+} and cPLA₂α^{-/-} SCG neurons ($p \leq 0.0015$; n = 5). However, unstimulated whole-cell N-current amplitude of cPLA₂α^{+/+} (851 ± 158 pA) and cPLA₂α^{-/-} SCG (698 ± 104 pA) neurons did not differ ($p \geq 0.35$; n = 5 neurons/group), indicating no obvious change in control channel activity in the absence of cPLA₂α (Fig 3E).

To test the extent of disrupted muscarinic signaling in the cPLA₂α^{-/-} SCG neurons, we performed two additional experiments. First, we eliminated the PTX preincubation step and tested cPLA₂α^{-/-} SCG neurons for N-current inhibition by M₂/M₄Rs. Under these conditions, Oxo-M now significantly inhibited N-current by 40.5 ± 4.08% ($p \leq 0.00005$, n = 10), indicating that the absence of cPLA₂α had no effect on a different muscarinic signal transduction pathway (Fig 3F). Second, we tested for differences in M-current between cPLA₂α^{+/+} and cPLA₂α^{-/-} SCG neurons, and found virtually identical average control and inhibited current amplitudes (Fig 4) indicating that cPLA₂α plays no role in regulating basal or modulated channel activity. Additionally, the magnitude of M-current inhibition following Oxo-M of cPLA₂α^{+/+} (50.6 ± 6.2%) and cPLA₂α^{-/-} (57.2 ± 3.7%) SCG neurons was not significant ($p \geq 0.4$; n = 13–14/group). These latter findings provide strong support for a model where M₁R signaling inhibits N-current by a transduction pathway that requires active cPLA₂α, by diverging from the pathway mediating M-current inhibition modulation.

cPLA₂α regulates action potential firing

Many plasma membrane ion channels are affected by interactions with phospholipids and their breakdown products. Therefore, to investigate whether cPLA₂α^{-/-} SCG neurons exhibit altered electrical properties, we examined the AP firing properties of cPLA₂α^{+/+} and cPLA₂α^{-/-} SCG neurons in the absence and presence of Oxo-M. Fig 5A and 5B illustrate increased rates of firing in both types of neurons following exposure to Oxo-M. The difference in firing rate




Fig 3. Oxo-M elicits reduced N-current inhibition in cPLA₂α^{-/-} SCG neurons. (A) Schematic of conditions used to isolate N-current in mouse SCG neurons. Cells were preincubated in PTX at least 5 hours prior to recording. (B) Summary bar graph of average N-current inhibition by Oxo-M in cPLA₂α^{-/-} and cPLA₂α^{+/+} SCG neurons.

***p* ≤ 0.0015, cPLA₂α^{-/-} % inhibition compared to cPLA₂α^{+/+} % inhibition using a two-tailed, *t*-test for two means

(n = 5). Individual current traces from (C) cPLA₂α^{+/+} compared to (D) cPLA₂α^{-/-} SCG neurons. Black traces, Control; red traces, Oxo-M. (E) Summary of average whole-cell N-current amplitude (NS, $p \geq 0.44$, n = 5). (F) Summary bar graph showing that in the absence of PTX, significant membrane-delimited N-current inhibition by Oxo-M remains in cPLA₂α^{-/-} SCG neurons remains ($***p \leq 0.00005$, n = 10).

<https://doi.org/10.1371/journal.pone.0201322.g003>

was maintained with increasing amounts of injected current. Maximal firing rate occurred with 100 pA of injected current (Fig 5C and 5D). While cPLA₂α^{+/+} and cPLA₂α^{-/-} neurons did not differ in firing frequency following Oxo-M, cPLA₂α^{-/-} neurons exhibited unanticipated,




Fig 4. M-current inhibition by Oxo-M remains robust in cPLA₂α^{-/-} SCG neurons. (A) Summary bar graph of the average M-current inhibition in cPLA₂α^{+/+} ($***p \leq 4 \times 10^{-6}$; n = 13) and cPLA₂α^{-/-} ($***p \leq 6 \times 10^{-5}$; n = 14) neurons following Oxo-M. (B) Schematic of the signaling cascade inhibiting M-current. Example time courses and selected individual traces from cPLA₂α^{+/+} (C-D) and cPLA₂α^{-/-} (E-F) neurons.

<https://doi.org/10.1371/journal.pone.0201322.g004>

increased firing frequency under control conditions when compared to cPLA₂α^{+/+} neurons that was maintained regardless of the amount of current injected (Fig 5E and 5F); however, these increases did not reach significance.

cPLA₂α^{+/+} SCG neurons normally fired several APs and then adapted despite continued current injection. A small percentage (14%) of cells fired only 1 AP (n = 5/34 recordings). We realized the sampling time in the prior experiment may have been too short to reveal significant differences in firing frequencies. Indeed, when the current injection time was increased from 400 to 1,000 msec, significant differences in basal firing frequency resulted (Fig 6A and 6B). 50% of cPLA₂α^{-/-} neurons (11/22) fired for the duration of the 1,000 msec current injection, whereas 82% of cPLA₂α^{+/+} neurons (27/33) adapted and ceased firing by 750 msec. We quantitated the underlying changes in the AP waveform (see S2 Fig) of phasic and tonic neurons by plotting duration of interpulse interval (IPI) against interval number and found




Fig 5. The absence of cPLA₂α alters AP firing in SCG neurons. (A-B) Examples of SCG AP firing elicited with 100 pA. Black traces, control; Red traces, 2 min after Oxo-M. (C-D) Current-frequency plots show that firing frequency increases with Oxo-M (red circles). (E) Current-frequency plots show that cPLA₂α^{-/-} neurons (solid circles) exhibit slightly elevated firing frequency over cPLA₂α^{+/+} neurons (open circles). (F) Firing frequency of cPLA₂α^{-/-} (solid circles) and cPLA₂α^{+/+} (open circles) cells following Oxo-M.

<https://doi.org/10.1371/journal.pone.0201322.g005>

shorter IPIs during control firing for cPLA₂α^{-/-} compared to cPLA₂α^{+/+} neurons (Fig 6C and 6E). Moreover, the time from the trough of the after hyperpolarization (AHP) to the threshold of the subsequent AP significantly decreased (Fig 6F). Consistent with these changes, the latency to the first AP (first latency) occurred in approximately half the time in cPLA₂α^{-/-} compared to cPLA₂α^{+/+} neurons (Fig 6F). We also observed consistent small increases in both the resting membrane potential (Fig 6G) and AP amplitude (Fig 6H) with various amounts of current injected; however, these changes did not reach significance. Additionally, no change in the voltage difference between the AHP and threshold of the subsequent AP, peak voltage of the AP overshoot, and AHP amplitude were observed (Fig 6I). Lastly, we measured different aspects of the AP duration (Fig 6J). We found no differences in spike width, duration of the rising phase of the AP (Rise Phase), duration of the falling phase, measured either from the peak of the AP to 1/3 of the AP's height (Falling Phase) or from the peak of the AP to the AHP (Peak to Trough). The observed changes resulted in a doubling of basal firing rate for cPLA₂α^{-/-} compared to cPLA₂α^{+/+} neurons as measured by the number of APs/second during current injection of 100 pA (Fig 6E, open vs grey bars). In contrast, firing frequency of both cPLA₂α^{-/-} and cPLA₂α^{+/+} neurons increased to a similar extent following exposure to Oxo-M (Fig 6D and 6E, red bars).

Discussion

This study examined the role of cPLA₂α in regulating phospholipid association with N-channels in SCG neurons. We took a multidisciplinary approach to test an emerging model of channel modulation where multiple phospholipases including cPLA₂α act in highly specific ways to metabolize phospholipids such as PIP₂ at or near N-channels following M₁R stimulation. Our working model provides a high degree of selective and local control over phospholipid interaction with N-channels. This is in contrast to a model where PLC activity reduces bulk PIP₂ levels in the cell membrane, which indirectly lowers phospholipid levels near N-channels [24]. Importantly, our data reconcile previous differences surrounding the role of cPLA₂α in N-channel modulation by G_q signaling and reveal a broader role for cPLA₂α in regulating membrane excitability.

The pharmacological evidence reported here supports a mechanism of modulation where N-current inhibition by M₁R stimulation requires cPLA₂α in addition to PLC. Antagonizing cPLA₂α with OPC reduced N-current inhibition, recorded in the perforated-patch configuration (Fig 1E and 1F). We discovered that in order to antagonize N-current inhibition by Oxo-M, a longer pre-incubation period with OPC is required most likely due to a greater maintained intracellular cPLA₂α concentration with the perforated-patch configuration compared to the whole-cell configuration. The longer preincubation time may allow more OPC to cross the plasma membrane, enter the cell, and inhibit additional cPLA₂α molecules that remain during perforated-patch recordings. Thus, we suggest that the most likely reason OPC did not prevent N-current modulation in a previous study is due to technical differences between the recording configurations [21, 24]. Additional antagonists of cPLA₂α (AACOCF₃, DEDA, and MAFP) also reduce whole-cell N-current inhibition by Oxo-M (Fig 1; [20, 21]), documenting that OPC's actions are not some unusual nonspecific effect. Lastly, OPC minimizes Ca²⁺ current inhibition by Oxo-M in PFC pyramidal neurons, extending the potential importance of PLA₂ in M₁R signaling to central neurons (S1 Fig).

Knockout mouse studies provide genetic evidence that N-current inhibition by M₁R signaling requires cPLA₂α by showing that cPLA₂α^{-/-} SCG neurons exhibited little, while cPLA₂α^{+/+} neurons exhibited robust N-current inhibition by Oxo-M (Fig 3). This interpretation of the data takes into account evidence that cPLA₂α^{-/-} SCG neurons maintain normal functioning of




Fig 6. Decreases in time from AHP to threshold account for increased firing of cPLA₂α^{-/-} SCG neurons. (A-B) Examples of differences in AP firing during a 1 sec injection of 100 pA of current. (C) IPI is significantly shorter in cPLA₂α^{-/-} (solid circles) compared to cPLA₂α^{+/+} (open circles) cells at all intervals (*p ≤ 0.05; n = 17–23 cells/data point). (D) Following exposure to Oxo-M, IPI interval lengths of cPLA₂α^{-/-} (solid circles) and cPLA₂α^{+/+} (open circles) cells superimpose (n = 8–18 cells/data point). (E) cPLA₂α^{-/-} neurons (n = 22) compared to cPLA₂α^{+/+} neurons (n = 34) exhibit increased basal (open bars) frequency of firing (**p ≤ 0.00015), but no difference in frequencies (p = 0.377)

following Oxo-M (red bars). Both cPLA₂α^{+/+} ($***p \leq 6 \times 10^{-5}$; n = 18) and cPLA₂α^{-/-} ($**p \leq 0.005$; n = 8) neurons exhibit increases in firing frequency following Oxo-M. (E-J) Open bars, cPLA₂α^{+/+} neurons; grey bars, cPLA₂α^{-/-} neurons, red bars, 10 μM Oxo-M. All analyses were performed on APs elicited with 100 pA unless otherwise specified. Properties of APs were measured from the 3rd AP of a train from 3 sequential traces and averaged for each recording. (F) Decreased latency to first firing ($*p \leq 0.05$) and time from the trough of the AHP to threshold ($*p \leq 0.05$) underlie the changes in IPI (n = 25–33 cells/group). (G) Resting potential and (H) AP amplitude of cPLA₂α^{+/+} (open bars) vs cPLA₂α^{-/-} (grey bars) SCG neurons were not significantly different ($p > 0.05$; n = 15–18) across a range of current injections. (I) Summary of average voltage change from AHP to threshold during an 80 pA current injection (n = 17 cells/group), peak AP (n = 26–27 cells/group), and maximal after hyperpolarization (n = 26–27 cells/group). See [S2 Fig](#) for a schematic and further details of measurements. (J) Summary of the AP duration. Spike Width, measured at 1/2 the AP amplitude; Rising Phase, measured at 1/3 the AP potential to the peak AP; Falling Phase, measured from the peak AP to 1/3 the AP potential; Peak to Trough, measured from the peak AP to the AHP (n = 26–27 cells/group).

<https://doi.org/10.1371/journal.pone.0201322.g006>

all other components of the slow pathway. **First**, no significant differences between control N-current amplitude in cPLA₂α^{+/+} vs cPLA₂α^{-/-} SCG neurons were found, showing that N-channels exhibit normal activity ([Fig 3E](#)). **Second**, AA inhibited whole-cell currents in cPLA₂α^{-/-} neurons [19], demonstrating that channel sensitivity to a lipid signaling molecule downstream of cPLA₂α remains unchanged. Complementary to these findings, imaging studies revealed that cPLA₂α^{-/-} neurons release less fatty acid following exposure to Oxo-M, when compared to cPLA₂α^{+/+} SCG neurons, indicating diminished downstream signaling [19]. **Third**, no significant differences between control M-current amplitude in cPLA₂α^{+/+} vs cPLA₂α^{-/-} SCG neurons were found, showing that M-channels exhibit normal activity ([Fig 4A](#)). **Fourth**, M-current inhibition by Oxo-M remained robust in cPLA₂α^{-/-} SCG neurons ([Fig 4](#)) with no significant change in the magnitude of M-current inhibition in cPLA₂α^{-/-} SCG neurons, indicating no change in M₁Rs, G_q, or PLC, key players in the slow pathway. **Fifth**, the absence of cPLA₂α appears to affect only specific aspects of N-current modulation by M₁Rs with no effect on membrane-delimited M₂/M₄R signaling or M-current inhibition by M₁R signaling. Alterations in unknown components in cPLA₂α^{-/-} neurons might account for these changes rather than loss of cPLA₂α. However, our Ab studies tested the consequences of an acute loss of cPLA₂α activity in SCG neurons. Dialyzing wild-type neurons with cPLA₂α Ab prevented N- but not M-inhibition by Oxo-M ([Fig 2G–2I](#)), consistent with the knockout findings. Furthermore, Abs to sPLA₂ had no effect on N-current, demonstrating a specific action of the cPLA₂α Ab in blocking the slow pathway ([Fig 2B and 2C](#)). These additional findings favor a model where N-current inhibition by M₁Rs requires PIP₂ breakdown by cPLA₂α. In contrast, activated PLC is sufficient to cause M-current inhibition, revealing pathway divergence downstream of PLC with M- and N-current modulation by M₁Rs.

PIP₂ is thought to play a critical role in regulating Ca²⁺ channel activity where a bound PIP₂ molecule facilitates coupling of voltage-sensing to channel opening [22, 24, 25, 28]. A requirement for cPLA₂α is compatible with the idea that PIP₂ bound to N-channels is selectively metabolized in situ by activated cPLA₂α following M₁R stimulation. Imaging studies document muscarinic stimulation of PIP₂ breakdown occurring with a similar time course to Ca²⁺ current inhibition [24, 45]. The finding that antagonizing PLC blocks M- and N-current inhibition [21, 24, 36] complements these imaging studies and demonstrates that PLC activity is necessary for M₁R modulation of both currents. However, these experiments do not provide direct evidence that rules out a requirement for cPLA₂α during N-current modulation. Indeed, our studies document that preincubation with OPC, dialysis with a selective cPLA₂α Ab, or the absence of cPLA₂α, has no effect on M-current inhibition by M₁Rs. These findings are consistent with a divergent signaling pathway where PIP₂ dissociation from K⁺ channels, followed by breakdown by PLC, is necessary and sufficient for M-current inhibition. Minimal L- and N-current inhibition by Oxo-M occurred under these same conditions [19, 20] suggesting that

PIP₂ metabolism by PLC is insufficient for Ca²⁺ channel inhibition and consistent with a required downstream role for cPLA₂α.

The requirement for additional phospholipases would protect N-channels from local Ca²⁺ influx chronically activating PLC to metabolize PIP₂. Loss of PIP₂ would stabilize channels in the closed state. These differences in M- versus N-current modulation by the slow pathway raise further intriguing questions about how different phospholipases might reside in channel microdomains or show varied affinities for different types of channels. These differences would impact which signaling molecules are generated locally to uniquely modulate N-channel activity. Recent evidence suggests that in addition to PIP₂, other anionic phospholipids such as phosphatidylserine may bind specific sites on Ca²⁺ channel subunits that also may regulate and participate in channel modulation [46, 47]. From the same start point (e.g., a phospholipid molecule bound to an M- or N-channel), varied channel activity could occur as a result of phospholipid metabolism by different phospholipases. Thus, from moment to moment, differential phospholipase access to N-channels could give rise to varied current modulation by M₁Rs with the potential to create highly localized synaptic plasticity.

Lastly, we examined cPLA₂α's effect on membrane excitability to test for its importance under more physiological conditions. In other SCG preparations, different subgroups of neurons were distinguished based on different AP firing patterns including *i*) firing of just one AP before adapting, *ii*) phasic firing of several AP before adapting and *iii*) tonic firing throughout the current injection pulse [48–49]. The vast majority of cPLA₂α^{+/+} neurons exhibited phasic bursting as illustrated in **Figs 5A and 6A**. No cPLA₂α^{+/+} neurons were tonically active and only 5/34 neurons fired single APs before adapting. Our studies unexpectedly revealed that the absence of cPLA₂α dramatically increases AP firing in SCG neurons (**Figs 5 and 6**). These findings suggest that cPLA₂α acts in a similar manner on N-channel activity in all types of mouse SCG neurons.

We interrogated the AP firing of phasic and tonically active neurons in more detail. A reduced latency to the first AP along with a shortened period of membrane repolarization following the AHP, and loss of spike adaptation can account for the increased AP frequency of firing. Resting membrane potential, threshold depolarization, AP amplitude, and AHP amplitude, and spike width did not change significantly (**Fig 6G–6J**). In contrast, the absence of cPLA₂α had little effect on increased firing following Oxo-M most likely because the firing rate already had reached maximal rates for SCG neurons, calculated to be 20–25 Hz [51]. Alternatively, increased SCG neuron firing that normally follows exposure to Oxo-M is attributed largely to inhibition of M-current [52], and we have shown that M-current is insensitive to the absence of cPLA₂α consistent with the similar observed firing frequencies in cPLA₂α^{+/+} and cPLA₂α^{-/-} neurons (**Fig 6D and 6H**). Increased basal AP frequency in cPLA₂α^{-/-} neurons suggests that tonic cPLA₂α activity normally suppresses membrane excitability in wild-type neurons. Inward Ca²⁺ currents typically contribute to the duration of the AP overshoot; however, no obvious change occurred in the overshoot duration including the down slope of the AP (**Fig 6**). Therefore, we suspect that in the absence of cPLA₂α other channels sensitive to membrane PIP₂ levels and/or its metabolites may exhibit altered tonic activity in cPLA₂α^{-/-} neurons, whereas N-channels only become susceptible to the actions of cPLA₂α following muscarinic stimulation.

A large number of channels expressed by SCG neurons exhibit sensitivity to phospholipids and their downstream metabolites. K⁺ channels determine the AP duration, frequency, and ability to fire repetitively [53]. In SCG neurons, a number of K⁺ currents control the length of the AHP including small Ca²⁺-activated K⁺ (SK3) currents [54, 55] and currents arising from the Kv2 channel family [56, 57]. Many of these types of K⁺ channels in SCG neurons bind PIP₂ [58, 59] however, not all PIP₂ sensitive K⁺ channels are affected by cPLA₂α since we have

shown that it has little effect on M-current. Some K⁺ channels, e.g., SK and BK channels are enhanced by both PIP₂ and cPLA₂α's metabolite AA [60–63]; whereas other channel activity is enhanced by PIP₂ but inhibited by AA [64]. Additionally PIP₂ shifts HCN channel open probability versus test potential ~20 mV in the negative direction, increasing rates of neuronal firing [65, 66]. These channels are also present in SCG neurons [50] and therefore an increase in their activity may participate in increasing cell firing in cPLA₂α^{-/-} SCG neurons. Lastly, free fatty acids, including AA, inhibit a number of different Na_v channels often by promoting inactivation (see N'Avanzo 2016 [67] for examples). Loss of AA release by cPLA₂α from phospholipids would be predicted to lower Na_v channel inactivation and could underlie the long-lasting spiking that we observed in cPLA₂α^{-/-} SCG neurons. These examples underscore how such varied changes in activity of multiple channel types make it virtually impossible to determine how many channel types in SCG neurons might be sensitive to cPLA₂α activity and therefore exhibit gating changes in cPLA₂α^{-/-} SCG neurons.

Conclusions

cPLA₂α participates in various neurophysiological and neuropathophysiological events, including neurotransmitter release, long-term potentiation, membrane remodeling, neuronal death following cerebral ischemia, neurodegeneration and apoptosis [5, 6, 68, 69]. We have found at the cellular level, that cPLA₂α participates in whole-cell N-current modulation by M₁R signaling. Our findings that AP firing frequency increases with loss of cPLA₂α expression reveals a role for tonic lipid processing in regulating membrane excitability that may underlie some of cPLA₂α's functions at the systems level. Thus, our findings identify two new roles for cPLA₂α: mediating N-channel inhibition by M₁R signaling and regulating membrane excitability.

Supporting information

S1 Methods. Method for dissociating rat prefrontal cortical neurons. Acutely dissociated pyramidal neurons from the prefrontal cortex (PFC) of young adult (2–4 weeks-old) Sprague-Dawley rats were obtained by removing the anterior aspect of the cortex following decapitation. Pieces were placed in DPBS at 4°C. PFC pieces were manually dissected into smaller pieces with a scalpel blade, and digested with papain (2 mg/ml) (Sigma) in Neurobasal-A medium (Life Technologies) bubbled with a 95% O₂/5% CO₂ gas mixture at 37°C in a shaking water bath for 60 minutes. After enzyme treatment, tissues were washed with Neurobasal-A medium containing bovine serum albumin (1 mg/ml) (Sigma) and trypsin inhibitor (1 mg/ml) (Sigma). Tissues were transferred into Neurobasal-A medium supplemented with 20 μl/ml of B27 (Invitrogen), 10% fetal bovine serum, 0.5 mM glutamine, and penicillin (100 U/ml)-streptomycin (0.1 mg/ml). Cortical neurons were dissociated by gentle trituration with a fire-polished Pasteur pipette; the supernatants after trituration were collected and mixed. Dissociated PFC neurons were then plated onto poly-L-lysine-coated glass coverslips in 25 mm² dishes and placed at 37°C in a CO₂ (5%) humidified incubator. Cells were pretreated with PTX for at least 5 hours before recording.
(PDF)

S1 Fig. OPC eliminates whole-cell Ca²⁺ current inhibition by Oxo-M recorded from dissociated, large pyramidal-shaped neurons. (A) Bath application of Oxo-M (10 μM) inhibits the whole-cell Ca²⁺ current from a PFC pyramidal neuron shown in the plot of current amplitude vs time (left) and in individual sweeps (right) taken from the time course. (B) In contrast, OPC (10 μM) blocked current inhibition shown in the plot of current amplitude vs time (left) and

in the individual sweeps (right) taken from the time course.
(PDF)

S2 Fig. Schematic of how the different aspects of APs, presented in Fig 6C–6J, were measured. Spike Width, duration of AP at V^{1/2} of the AP amplitude. Rising Phase, time from V^{1/3} of AP to peak of AP. Falling Phase, time from AP peak to V^{1/3} of AP. Peak to Trough, time from AP peak to AHP.
(PDF)

Acknowledgments

We thank Bruce Bean and Leslie Satin for helpful discussions about action potential activity. We thank Mandy Roberts-Crowley and Tora Mitra-Ganguli for reading earlier versions of the manuscript.

Author Contributions

Conceptualization: Liwang Liu, Joseph V. Bonventre, Ann R. Rittenhouse.

Data curation: Liwang Liu.

Formal analysis: Liwang Liu, Ann R. Rittenhouse.

Funding acquisition: Joseph V. Bonventre, Ann R. Rittenhouse.

Investigation: Liwang Liu.

Methodology: Liwang Liu, Joseph V. Bonventre.

Project administration: Ann R. Rittenhouse.

Resources: Joseph V. Bonventre, Ann R. Rittenhouse.

Supervision: Ann R. Rittenhouse.

Writing – original draft: Liwang Liu.

Writing – review & editing: Liwang Liu, Joseph V. Bonventre, Ann R. Rittenhouse.

References

1. Zhou H, Das S, Murthy KS. Erk1/2- and p38 MAP kinase-dependent phosphorylation and activation of cPLA₂ by m3 and m2 receptors. *Am J Physiol Gastrointest Liver Physiol*. 2003; 284: G472–480. <https://doi.org/10.1152/ajpgi.00345.2002> PMID: 12576304.
2. Leslie CC. Cytosolic phospholipase A(2): physiological function and role in disease. *Journal of lipid research*. 2015; 56: 1386–1402. <https://doi.org/10.1194/jlr.R057588> PMID: 25838312; Central PMCID: PMC4513982.
3. Clark JD, Lin LL, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, et al. A novel arachidonic acid-selective cytosolic PLA₂ contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. *Cell*. 1991; 65: 1043–1051. PMID: 1904318.
4. Bonventre JV. Roles of phospholipases A₂ in brain cell and tissue injury associated with ischemia and excitotoxicity. *J Lipid Mediat Cell Signal*. 1997; 16: 199–208. PMID: 9246608.
5. Sapirstein A, Bonventre JV. Phospholipases A₂ in ischemic and toxic brain injury. *Neurochem Res*. 2000; 25: 745–753. PMID: 10905638.
6. Farooqui AA, Ong WY, Horrocks LA. Inhibitors of brain phospholipase A₂ activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. *Pharmacol Rev*. 2006; 58: 591–620. <https://doi.org/10.1124/pr.58.3.7> PMID: 16968951.
7. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, et al. Phospholipase A₂ reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. *Nature Neurosci*. 2008; 11:

- 1311–1318. <https://doi.org/10.1038/nn.2213> PMID: 18931664; PubMed Central PMCID: PMCPMC2597064.
8. Lopez-Vales R, Ghasemlou N, Redensek A, Kerr BJ, Barbayianni E, Antonopoulou G, et al. Phospholipase A₂ superfamily members play divergent roles after spinal cord injury. *FASEB J*. 2011; 25: 4240–4252. <https://doi.org/10.1096/fj.11-183186> PMID: 21868473; PubMed Central PMCID: PMCPMC3236632.
 9. Liu NK, Titsworth WL, Zhang YP, Xhafa AI, Shields CB, Xu XM. Characterizing phospholipase A₂-induced spinal cord injury—a comparison with contusive spinal cord injury in adult rats. *Transl Stroke Res*. 2011; 2: 608–618. <https://doi.org/10.1007/s12975-011-0089-x> PMID: 23585818; PubMed Central PMCID: PMCPMC3622278.
 10. Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. *ACS Chem Neurosci*. 2014; 5: 459–467. <https://doi.org/10.1021/cn500058v> PMID: 24786695; PubMed Central PMCID: PMCPMC4063504.
 11. Li J, Al-Khalili O, Ramosevac S, Eaton DC, Denson DD. Protein-protein interaction between cPLA₂ and splice variants of alpha-subunit of BK channels. *Am J Physiol Cell Physiol*. 2010; 298: C251–262. <https://doi.org/10.1152/ajpcell.00221.2009> PMID: 19940072; PubMed Central PMCID: PMCPMC3774341.
 12. Le TD, Shirai Y, Okamoto T, Tatsukawa T, Nagao S, Shimizu T, et al. Lipid signaling in cytosolic phospholipase A₂-alpha-cyclooxygenase-2 cascade mediates cerebellar long-term depression and motor learning. *Proc Natl Acad Sci USA*. 2010; 107: 3198–3203. <https://doi.org/10.1073/pnas.0915020107> PMID: 20133605; PubMed Central PMCID: PMCPMC2840314.
 13. Wang DJ, Su LD, Wang YN, Yang D, Sun CL, Zhou L, et al. Long-term potentiation at cerebellar parallel fiber-Purkinje cell synapses requires presynaptic and postsynaptic signaling cascades. *J Neurosci*. 2014; 34: 2355–2364. <https://doi.org/10.1523/JNEUROSCI.4064-13.2014> PMID: 24501374.
 14. Su LD, Wang DJ, Yang D, Shen Y, Hu YH. Retrograde cPLA₂α/arachidonic acid/2-AG signaling is essential for cerebellar depolarization-induced suppression of excitation and long-term potentiation. *Cerebellum*. 2013; 12: 297–9. <https://doi.org/10.1007/s12311-012-0444-9> PMID: 23307660.
 15. Shen W, Tian X, Day M, Ulrich S, Tkatch T, Nathanson NM, et al. Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. *Nature Neurosci*. 2007; 10: 1458–1466. <https://doi.org/10.1038/nn1972> PMID: 17906621.
 16. Roberts-Crowley ML, Rittenhouse AR. Arachidonic acid inhibition of L-type calcium (Ca_v1.3b) channels varies with accessory Ca_vβ subunits. *J Gen Physiol*. 2009; 133: 387–403. <https://doi.org/10.1085/jgp.200810047> PMID: 19332620; PubMed Central PMCID: PMCPMC2699108.
 17. Roberts-Crowley ML, Mitra-Ganguli T, Liu L, Rittenhouse AR. Regulation of voltage-gated Ca²⁺ channels by lipids. *Cell Calcium*. 2009; 45: 589–601. <https://doi.org/10.1016/j.ceca.2009.03.015> PMID: 19419761; PubMed Central PMCID: PMCPMC2964877.
 18. Meves H. Modulation of ion channels by arachidonic acid. *Prog Neurobiol*. 1994; 43: 175–186. PMID: 7526418.
 19. Liu L, Zhao R, Bai Y, Stanish LF, Evans JE, Sanderson MJ, et al. M1 muscarinic receptors inhibit L-type Ca²⁺ current and M-current by divergent signal transduction cascades. *J Neurosci*. 2006; 26: 11588–11598. <https://doi.org/10.1523/JNEUROSCI.2102-06.2006> PMID: 17093080.
 20. Liu L, Roberts ML, Rittenhouse AR. Phospholipid metabolism is required for M₁ muscarinic inhibition of N-type calcium current in sympathetic neurons. *Eu Biophys J*. 2004; 33: 255–64. <https://doi.org/10.1007/s00249-003-0387-7> PMID: 15004729.
 21. Liu L, Rittenhouse AR. Arachidonic acid mediates muscarinic inhibition and enhancement of N-type Ca²⁺ current in sympathetic neurons. *Proc Natl Acad Sci USA*. 2003; 100: 295–300. <https://doi.org/10.1073/pnas.0136826100> PMID: 12496347; PubMed Central PMCID: PMC140955.
 22. Suh BC, Hille B. Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. *Curr Opin Neurobiol*. 2005; 15(3): 370–378. <https://doi.org/10.1016/j.conb.2005.05.005> PMID: 15922587.
 23. Heneghan JF, Mitra-Ganguli T, Stanish LF, Liu L, Zhao R, Rittenhouse AR. The Ca²⁺ channel beta subunit determines whether stimulation of Gq-coupled receptors enhances or inhibits N current. *J Gen Physiol*. 2009; 134: 369–384. <https://doi.org/10.1085/jgp.200910203> PMID: 19858357; PubMed Central PMCID: PMCPMC2768801.
 24. Gamper N, Reznikov V, Yamada Y, Yang J, Shapiro MS. Phosphatidylinositol [correction] 4,5-bisphosphate signals underlie receptor-specific Gq/11-mediated modulation of N-type Ca²⁺ channels. *J Neurosci*. 2004; 24: 10980–10992. <https://doi.org/10.1523/JNEUROSCI.3869-04.2004> PMID: 15574748.
 25. Suh BC, Leal K, Hille B. Modulation of high-voltage activated Ca(2+) channels by membrane phosphatidylinositol 4,5-bisphosphate. *Neuron*. 2010; 67: 224–238. <https://doi.org/10.1016/j.neuron.2010.07.001> PMID: 20670831; PubMed Central PMCID: PMCPMC2931829.

26. Michailidis IE, Zhang Y, Yang J. The lipid connection-regulation of voltage-gated Ca(2+) channels by phosphoinositides. *Pflugers Archiv: Eu J Physiol*. 2007; 455: 147–155. <https://doi.org/10.1007/s00424-007-0272-9> PMID: 17541627.
27. Delmas P, Coste B, Gamper N, Shapiro MS. Phosphoinositide lipid second messengers: new paradigms for calcium channel modulation. *Neuron*. 2005; 47: 179–182. <https://doi.org/10.1016/j.neuron.2005.07.001> PMID: 16039560.
28. Wu L, Bauer CS, Zhen XG, Xie C, Yang J. Dual regulation of voltage-gated calcium channels by PtdIns(4,5)P₂. *Nature*. 2002; 419(6910):947–52. <https://doi.org/10.1038/nature01118> PMID: 12410316.
29. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, et al. Reduced fertility and post-ischaemic brain injury in mice deficient in cytosolic phospholipase A₂. *Nature*. 1997; 390: 622–625. <https://doi.org/10.1038/37635> PMID: 9403693.
30. Liu L, Barrett CF, Rittenhouse AR. Arachidonic acid both inhibits and enhances whole cell calcium currents in rat sympathetic neurons. *Am J Physiol Cell Physiol*. 2001; 280: C1293–1305. <https://doi.org/10.1152/ajpcell.2001.280.5.C1293> PMID: 11287343.
31. Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. *Life Sci*. 1993; 52: 441–448. PMID: 8441326.
32. Suh BC, Hille B. Recovery from muscarinic modulation of M current channels requires phosphatidylinositol 4,5-bisphosphate synthesis. *Neuron*. 2002; 35: 507–520. PMID: 12165472.
33. Winks JS, Hughes S, Filippov AK, Tatulian L, Abogadie FC, Brown DA, et al. Relationship between membrane phosphatidylinositol-4,5-bisphosphate and receptor-mediated inhibition of native neuronal M channels. *J Neurosci*. 2005; 25: 3400–3413. <https://doi.org/10.1523/JNEUROSCI.3231-04.2005> PMID: 15800195.
34. Zhang H, Craciun LC, Mirshahi T, Rohacs T, Lopes CMB, Jin T, et al. PIP(2) activates KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents. *Neuron*. 2003; 37: 963–975. PMID: 12670425.
35. Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. *J Biol Chem*. 1994; 269: 3563–3567. PMID: 8106399.
36. Vivas O, Castro H, Arenas I, Elías-Viñas D, García DE. PIP₂ hydrolysis is responsible for voltage independent inhibition of Ca_v2.2 channels in sympathetic neurons. *Biochem Biophys Res Com*. 2013; 432: 275–280. <https://doi.org/10.1016/j.bbrc.2013.01.117> PMID: 23396054.
37. Liu L, Rittenhouse AR. Pharmacological discrimination between muscarinic receptor signal transduction cascades with bethanechol chloride. *Br J Pharmacol*. 2003; 138: 1259–1270. <https://doi.org/10.1038/sj.bjp.0705157> PMID: 12711626; PubMed Central PMCID: PMC1573771.
38. Balsinde J, Dennis EA. Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages. *J Biol Chem*. 1996; 271: 6758–6765. PMID: 8636097.
39. Emslie KS, Zhou W, Jones SW. LHRH and GTP-gamma-S modify calcium current activation in bullfrog sympathetic neurons. *Neuron*. 1990; 5: 75–80. PMID: 2164405.
40. Bernheim L, Mathie A, Hille B. Characterization of muscarinic receptor subtypes inhibiting Ca₂₊ current and M current in rat sympathetic neurons. *Proc Natl Acad Sci USA*. 1992; 89: 9544–9548. PMID: 1329101.
41. Shapiro MS, Gomeza J, Hamilton SE, Hille B, Loose MD, Nathanson NM, et al. Identification of subtypes of muscarinic receptors that regulate Ca₂₊ and K⁺ channel activity in sympathetic neurons. *Life Sci*. 2001; 68: 2481–2487. PMID: 11392616.
42. Kennedy BP, Payette P, Mudgett J, Vadas P, Pruzanski W, Kwan M, et al. A natural disruption of the secretory group II phospholipase A₂ gene in inbred mouse strains. *J Biol Chem*. 1995; 270: 22378–22385. PMID: 7673223.
43. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM. The secretory phospholipase A₂ gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. *Cell*. 1995; 81: 957–966. PMID: 7781071.
44. Martínez-Pinna J, Lamas JA, Gallego R. Calcium current components in intact and dissociated adult mouse sympathetic neurons. *Brain Res*. 2002; 951:227–236. PMID: 12270501.
45. Suh BC, Inoue T, Meyer T, Hille B. Rapid chemically induced changes of PtdIns(4,5)P₂ gate KCNQ ion channels. *Science*. 2006; 314: 1454–1457. <https://doi.org/10.1126/science.1131163> PMID: 16990515; PubMed Central PMCID: PMC3579521.
46. Kaur G, Pinggera A, Ortner NJ, Lieb A, Sinnegger-Brauns MJ, Yarov-Yarovoy V, et al. A Polybasic Plasma Membrane Binding Motif in the I-II Linker Stabilizes Voltage-gated CaV1.2 Calcium Channel Function. *J Biol Chem*. 2015; 290: 21086–21100. <https://doi.org/10.1074/jbc.M115.645671> PMID: 26100638; PubMed Central PMCID: PMC4543666.

47. Kim DI, Kang M, Kim S, Lee J, Park Y, Chang I, et al. Molecular Basis of the Membrane Interaction of the β_{2e} Subunit of Voltage-Gated Ca(2+) Channels. *Biophysical journal*. 2015; 109: 922–935. <https://doi.org/10.1016/j.bpj.2015.07.040> PMID: 26331250; PubMed Central PMCID: PMC4564829.
48. Jia Z, Bei J, Rodat-Despoix L, Liu B, Jia Q, Delmas P, et al. NGF inhibits M/KCNQ currents and selectively alters neuronal excitability in subsets of sympathetic neurons depending on their M/KCNQ current background. *J Gen Physiol*. 2008; 131: 575–587. <https://doi.org/10.1085/jgp.200709924> PMID: 18474635; PubMed Central PMCID: PMC4391251.
49. Springer MG, Kullmann PH, Horn JP. Virtual leak channels modulate firing dynamics and synaptic integration in rat sympathetic neurons: implications for ganglionic transmission in vivo. *J Physiol*. 2015; 593: 803–823. <https://doi.org/10.1113/jphysiol.2014.284125> PMID: 25398531; PubMed Central PMCID: PMC4398523.
50. Kullmann PH, Sikora KM, Clark KL, Arduini I, Springer MG, Horn JP. HCN hyperpolarization-activated cation channels strengthen virtual nicotinic EPSPs and thereby elevate synaptic amplification in rat sympathetic neurons. *J Neurophysiol*. 2016; 116: 438–447. <https://doi.org/10.1152/jn.00223.2016> PMID: 27146984; PubMed Central PMCID: PMC4976122.
51. Wheeler DW, Kullmann PH, Horn JP. Estimating use-dependent synaptic gain in autonomic ganglia by computational simulation and dynamic-clamp analysis. *J Neurophysiol*. 2004; 92: 2659–2671. <https://doi.org/10.1152/jn.00470.2004> PMID: 15212430.
52. Brown DA, Constanti A. Intracellular observations on the effects of muscarinic agonists on rat sympathetic neurones. *Br J Pharmacol*. 1980; 70: 593–608. PMID: 7470731; PubMed Central PMCID: PMC4398523.
53. Bean BP. The action potential in mammalian central neurons. *Nat Rev Neurosci*. 2007; 8: 451–465. <https://doi.org/10.1038/nrn2148> PMID: 17514198.
54. Davies PJ, Ireland DR, McLachlan EM. Sources of Ca²⁺ for different Ca(2+)-activated K+ conductances in neurones of the rat superior cervical ganglion. *J Physiol*. 1996; 495 (Pt 2): 353–366. PMID: 8887749.
55. Hosseini R, Benton DC, Dunn PM, Jenkinson DH, Moss GW. SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. *J Physiol*. 2001; 535 (Pt 2): 323–334. <https://doi.org/10.1111/j.1469-7793.2001.00323.x> PMID: 11533126; PubMed Central PMCID: PMC4398523.
56. Malin SA, Nerbonne JM. Delayed rectifier K+ currents, IK, are encoded by Kv2 alpha-subunits and regulate tonic firing in mammalian sympathetic neurons. *J Neurosci*. 2002; 22: 10094–10105. PMID: 12451110.
57. Liu PW, Bean BP. Kv2 channel regulation of action potential repolarization and firing patterns in superior cervical ganglion neurons and hippocampal CA1 pyramidal neurons. *J Neurosci*. 2014; 34: 4991–5002. <https://doi.org/10.1523/JNEUROSCI.1925-13.2014> PMID: 24695716; PubMed Central PMCID: PMC4398523.
58. Kruse M, Hille B. The phosphoinositide sensitivity of the K(v) channel family. *Channels*. 2013; 7: 530–536. <https://doi.org/10.4161/chan.25816> PMID: 23907203; PubMed Central PMCID: PMC4042488.
59. Delgado-Ramirez M, De Jesus-Perez JJ, Arechiga-Figueroa IA, Arreola J, Adney SK, Villalba-Galea CA, et al. Regulation of Kv2.1 channel inactivation by phosphatidylinositol 4,5-bisphosphate. *Sci Rep*. 2018; 8: 1769. <https://doi.org/10.1038/s41598-018-20280-w> PMID: 29379118; PubMed Central PMCID: PMC5788980.
60. Denson DD, Li J, Eaton DC. Co-localization of the alpha-subunit of BK-channels and c-PLA₂ in GH3 cells. *Biochem Biophys Res Com*. 2006; 350: 39–49. <https://doi.org/10.1016/j.bbrc.2006.08.193> PMID: 16997278.
61. Denson DD, Li J, Wang X, Eaton DC. Activation of BK channels in GH3 cells by a c-PLA₂-dependent G-protein signaling pathway. *J Neurophysiol*. 2005; 93:3146–56. <https://doi.org/10.1152/jn.00865.2004> PMID: 15647401.
62. Guerard P, Goirand F, Fichet N, Bernard A, Rochette L, Morcillo EJ, et al. Arachidonic acid relaxes human pulmonary arteries through K+ channels and nitric oxide pathways. *Eu J Pharm*. 2004; 501: 127–135. <https://doi.org/10.1016/j.ejphar.2004.08.007> PMID: 15464071.
63. Zhang M, Meng XY, Cui M, Pascal JM, Logothetis DE, Zhang JF. Selective phosphorylation modulates the PIP2 sensitivity of the CaM-SK channel complex. *Nat Chem Biol*. 2014; 10: 753–759. <https://doi.org/10.1038/nchembio.1592> PMID: 25108821; PubMed Central PMCID: PMC4420199.
64. Oliver D, Lien CC, Soom M, Baukowitz T, Jonas P, Fakler B. Functional conversion between A-type and delayed rectifier K⁺ channels by membrane lipids. *Science*. 2004; 304: 265–2670. <https://doi.org/10.1126/science.1094113> PMID: 15031437.

65. Zolles G, Klocker N, Wenzel D, Weisser-Thomas J, Fleischmann BK, Roeper J, et al. Pacemaking by HCN channels requires interaction with phosphoinositides. *Neuron*. 2006; 52: 1027–1036. <https://doi.org/10.1016/j.neuron.2006.12.005> PMID: 17178405.
66. Pian P, Bucci A, Robinson RB, Siegelbaum SA. Regulation of gating and rundown of HCN hyperpolarization-activated channels by exogenous and endogenous PIP₂. *J Gen Physiol*. 2006; 128: 593–604. <https://doi.org/10.1085/jgp.200609648> PMID: 17074978; PubMed Central PMCID: PMC2151583.
67. D'Avanzo N. Lipid Regulation of Sodium Channels. *Curr Top Membr*. 2016; 78: 353–407. <https://doi.org/10.1016/bs.ctm.2016.04.003> PMID: 27586290.
68. Hornfelt M, Edström A, Ekström PA. Upregulation of cytosolic phospholipase A₂ correlates with apoptosis in mouse superior cervical and dorsal root ganglia neurons. *Neurosci Lett*. 1999; 265: 87–90. PMID: 10327175.
69. Phillis JW, O'Regan MH. A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. *Brain Res Brain Res Rev*. 2004; 44:13–47. PMID: 14739001.